| Literature DB >> 35417719 |
Anna Köferle1, Andreas Schlattl1, Alexandra Hörmann1, Venu Thatikonda1, Alexandra Popa1, Fiona Spreitzer1, Madhwesh C Ravichandran1, Verena Supper1, Sarah Oberndorfer1, Teresa Puchner1, Corinna Wieshofer1, Maja Corcokovic1, Christoph Reiser1, Simon Wöhrle1, Johannes Popow1, Mark Pearson1, Javier Martinez2, Stefan Weitzer2, Barbara Mair3, Ralph A Neumüller4.
Abstract
Genetic networks are characterized by extensive buffering. During tumor evolution, disruption of functional redundancies can create de novo vulnerabilities that are specific to cancer cells. Here, we systematically search for cancer-relevant paralog interactions using CRISPR screens and publicly available loss-of-function datasets. Our analysis reveals >2,000 candidate dependencies, several of which we validate experimentally, including CSTF2-CSTF2T, DNAJC15-DNAJC19, FAM50A-FAM50B, and RPP25-RPP25L. We provide evidence that RPP25L can physically and functionally compensate for the absence of RPP25 as a member of the RNase P/MRP complexes in tRNA processing. Our analysis also reveals unexpected redundancies between sex chromosome genes. We show that chrX- and chrY-encoded paralogs, such as ZFX-ZFY, DDX3X-DDX3Y, and EIF1AX-EIF1AY, are functionally linked. Tumor cell lines from male patients with loss of chromosome Y become dependent on the chrX-encoded gene. We propose targeting of chrX-encoded paralogs as a general therapeutic strategy for human tumors that have lost the Y chromosome.Entities:
Keywords: CP: Cancer; DDX3X; DDX3Y; RPP25; RPP25L; cancer; genetic interaction; loss of chromosome Y; paralog; sex chromosomes; synthetic lethality
Mesh:
Substances:
Year: 2022 PMID: 35417719 DOI: 10.1016/j.celrep.2022.110636
Source DB: PubMed Journal: Cell Rep Impact factor: 9.423